Plain-English translation of NCT07313592 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study is testing whether ChromoSeq—a genetic analysis tool—can help doctors quickly and accurately identify the type of acute lymphoblastic leukemia a child or young adult has when they are first diagnosed. Researchers will collect a small sample of bone marrow or blood from 60 patients at the time of their initial workup and analyze it using this genetic sequencing method. The goal is to see if this tool can be used in real hospitals to help guide treatment decisions right from the start.
Acute lymphoblastic leukemia is a serious blood cancer that affects children and young adults, and different types of the disease may need different treatments. This study exists to see whether genetic testing with this tool can help doctors identify the specific type of leukemia faster and more accurately, so patients can get the best treatment for their particular cancer.
You likely qualify if…
You likely don't qualify if…
At the time of your initial diagnosis workup, you will have a small sample of bone marrow or blood (about 1 milliliter) collected, which will be sent for genetic analysis using the ChromoSeq test. After that initial sample collection, you will be followed by the research team for up to about 5 years to track how you respond to your treatment and how you are doing. This study does not change your regular cancer treatment—it simply adds one genetic test to help doctors better understand your specific leukemia.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
United States
Sponsor
Washington University School of Medicine
Collaborators
McDonnell Center
Enrollment target
~60 participants
Started
June 2026
Primary completion
July 2028
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Margaret Ferris, MD, PhD
Washington University School of Medicine
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.